A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

Inclusion Criteria:

1. Has the ability to provide informed consent to participate in the study, inaccordance with the International Council for Harmonisation (ICH) Good ClinicalPractice (GCP) Guideline E6 (R2) (2016) and applicable national and internationalregulations, before any protocol directed interventions are carried out.

2. Has an understanding, ability, and willingness to comply with Study procedures andrestrictions.

3. Is 16 years or older at the time of screening.

4. First approximately 50 participants: congenital Type 1 VWD with a residual VWFantigen and/or activity less than 40 IU/dL (40%) Next approximately 50 participants: Type 1 VWD with residual VWF antigen andactivity less than 50 IU/dL (50%) After the first approximately 100 participants: congenital Type 1, Type 2A, Type 2M,Type 2N, or Type 3 VWD Note: Participants may be enrolled if they have documented laboratory results forVWF antigen and activity within their medical records confirming their diagnosis (consistent with International Society on Thrombosis and Hemostasis [ISTH]/AmericanSociety of Hematology [ASH] diagnostic guidelines or British Society for Haematology [BSH]/ United Kingdom Haemophilia Centre Doctors; Organisation [UKHCDO] diagnosticguidelines). For Type 1 VWD in the first part of the study, participants also needto have a documented laboratory result within the last 2 years showing a VWF antigenand/or activity level less than 40 IU/dL. Participants meeting eligibility criteriabased on documented results will proceed with having samples collected at Screeningto further characterize their antigen and activity levels. These may be repeated upto 2 further times if the results are not consistent with their documented diagnosisand levels are greater than 40 IU/dL. If participants do not have confirmed results in their medical records as describedabove, the screening assessment may be repeated up to 2 further times to establishbaseline levels for inclusion.

5. Has symptomatic disease as defined by a history of bruising or bleeding events, andtypically experiencing bleeding symptoms every month.

Exclusion Criteria:

1. Has a personal history of venous or arterial thrombosis or thromboembolic disease,except for catheter-associated, superficial vein thrombosis events.

2. Has a significant family history of unprovoked thromboembolic events in first degreerelatives.

3. Has a congenital or acquired bleeding disorder other than VWD.

4. Has planned major surgery within the next 6 months.

5. Is pregnant or plans to become pregnant within the next 6 months.

6. Has any concurrent disease, treatment (including ongoing anticoagulation,antiplatelet, or non-steroidal anti-inflammatory drugs), condition, medication, orabnormality in clinical laboratory tests which may impact on the participant'sbleeding symptoms or affect their ability to complete the study, in theInvestigator's opinion.

7. Has received any investigational product within 30 days prior to screening.